00:30
Once-weekly treatment with tirzepatide showed superior glycaemic control measured using CGM compared with insulin degludec in participants with type 2 diabetes on metformin, with or without a SGLT2 inhibitor. These new data provide additional evidence to the effect of tirzepatide and potential (...) (The Lancet Diabetes & Endocrinology 10, 6 (2022))
00:30[Articles] Effects of subcutaneous tirzepatide versus placebo or semaglutide on pancreatic islet function and insulin sensitivity in adults with type 2 diabetes: a multicentre, randomised, double-blind, parallel-arm, phase 1 clinical trial -
Tim Heise, Andrea Mari, J Hans DeVries, Shweta Urva, Jing Li, Edward John Pratt, Tamer Coskun, Melissa K Thomas, Kieren J Mather, Axel Haupt, Zvonko Milicevic
Lancet Diab Endocrinol
The glycaemic efficacy of GIP/GLP-1 receptor agonist tirzepatide in type 2 diabetes results from concurrent improvements in key components of diabetes pathophysiology, namely ?-cell function, insulin sensitivity, and glucagon secretion. These effects were large and help to explain the remarkable (...) (The Lancet Diabetes & Endocrinology 10, 6 (2022))
00:30
In The Lancet Diabetes & Endocrinology, Amalia Gastaldelli and colleagues1 present their findings from SURPASS-3 MRI, a substudy of the randomised, open-label, parallel-group, phase-3 SURPASS-3 trial.2 It is the first study to date to assess the effect of a 52-week treatment with (...) (The Lancet Diabetes & Endocrinology 10, 6 (2022))
00:30
In their article in The Lancet Diabetes and Endocrinology, Tadej Battelino and colleagues1 report on a dedicated substudy of the parent SURPASS-3 randomised clinical trial, in which all three groups given the dual GLP-1 and GIP, tirzepatide (5 mg, 10 mg, or 15 mg weekly doses), had (...) (The Lancet Diabetes & Endocrinology 10, 6 (2022))
00:30
Type 2 diabetes is a complex disease with several key defects, including impaired insulin secretion, increased glucagon secretion, and insulin resistance, which is exacerbated by obesity. Thus, besides lifestyle measures, pharmacological therapy should aim to target most, if not all, of these (...) (The Lancet Diabetes & Endocrinology 10, 6 (2022))
00:30
Tirzepatide showed a significant reduction in LFC and VAT and ASAT volumes compared with insulin degludec in this subpopulation of patients with type 2 diabetes in the SURPASS-3 study. These data provide additional evidence on the metabolic effects of this novel dual GIP and GLP-1 receptor (...) (The Lancet Diabetes & Endocrinology 10, 6 (2022))